Skip to main content

Table 3 Subjects with Adverse Events: Incidence Rate ≥ 5%* (two or more subjects)

From: Subcutaneously administered Menopur(R), a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex(R) in subjects undergoing in vitro fertilization

Adverse Event

Menopur® n = 61

Repronex® n = 64

Abdominal cramps

13

(21.3)

14

(21.9)

Headache

13

(21.3)

13

(20.3)

Post retrieval pain

7

(11.5)

9

(14.1)

Nausea

6

(9.8)

10

(15.6)

Vaginal spotting

6

(9.8)

5

(7.8)

Abdominal fullness

5

(8.2)

7

(10.9)

Abdominal pain

5

(8.2)

4

(6.3)

Constipation

5

(8.2)

1

(1.6)

Respiratory disorder

4

(6.6)

4

(6.3)

Vaginal hemorrhage

2

(3.3)

4

(6.3)

Breast tenderness/pain

2

(3.3)

5

(7.8)

Malaise

2

(3.3)

4

(6.3)

Sinusitis

2

(3.3)

4

(6.3)

  1. *Values represent numbers (percentage) of subjects with adverse event.
Back to article page

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us